Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov:106:49-57.
doi: 10.1016/j.neubiorev.2018.12.005. Epub 2018 Dec 5.

Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment

Sandra D Comer  1 , Catherine M Cahill  2
Affiliations
Review

Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment

Sandra D Comer et al. Neurosci Biobehav Rev. 2019 Nov.

Abstract

Opioid overdoses, many of which are attributed to use of illicit fentanyl, are currently one of the leading causes of death in the U.S. Although fentanyl has been used safely for decades in clinical settings, the widespread use of illicit fentanyl is a recent phenomenon. Starting in 2013, illicitly manufactured fentanyl and its analogs began to appear on the streets. These substances were added to or sold as heroin, often unbeknownst to the user. Because fentanyl is so potent, only small amounts are needed to produce pharmacological effects, but the margin between safe and toxic doses is narrow. Surprisingly little is known about the exact signaling mechanisms underlying fentanyl-related respiratory depression or the effectiveness of naloxone in reversing this effect. Similarly, little is known about the ability of treatment medications such as buprenorphine, methadone, or naltrexone to reduce illicit fentanyl use. The present article reviews the receptor, preclinical and clinical pharmacology of fentanyl, and how its pharmacology may predict the effectiveness of currently approved medications for treating illicit fentanyl use.

Keywords: Abuse; Beta-arrestin; Buprenorphine; Efficacy; Fentanyl; Heroin; Illicit; Methadone; Naltrexone; Pain; Pharmacology; Self-administration; Subjective effects; Treatment.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
A. Pharmacological differences between fentanyl and prototypical opioid agonist morphine. Morphine binds to mu opioid receptors (MOR) and primarily produces signaling through activation of G-proteins, whereas fentanyl also activates beta-arrestin pathways that leads to respiratory depression. The enhanced respiratory depression of fentanyl compared to morphine may be due to their differences in intracellular signaling cascades. *Please note that equianalgesic conversion is dependent on route of administration and species. Opioid exposure prior to intracranial self-stimulation (ICSS) (B) or intravenous self-administration (IVSA) (C) produces activity predictive of increasing abuse potential. In contrast, pain prior to ICSS (B) or IVSA (C) has the opposite effect, where abuse potential is reduced. Note, the reduced abuse potential with prior pain to opioid exposure may not apply to individuals with comorbidities of post-traumatic stress disorder, depression and anxiety or the presence of catastrophizing (Evans & Cahill, 2016).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahmed SH, Walker JR, Koob GF, 2000. Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology 22 (4), 413. - PubMed
    1. Altarifi AA, Rice KC, Negus SS, 2015. Effects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity. J. Pharmacol. Exp. Ther 352 (2), 208–217. - PMC - PubMed
    1. Balster RL, Bigelow GE, 2003. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 70 (3), S13–S40. - PubMed
    1. Barrett AC, Cook CD, Terner JM, Craft RM, Picker MJ, 2001. Importance of sex and relative efficacy at the μ opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids. Psychopharmacology 158, 154–164. - PubMed
    1. Barrett AC, Smith ES, Picker MJ, 2003. Use of irreversible antagonists to determine the relative efficacy of μ-opioids in a pigeon drug discrimination procedure: Comparison of β-funaltrexamine and clocinnamox. J. Pharmacol. Exp. Ther 306 (3), 1061–1070. - PubMed

Publication types

MeSH terms